MODERNA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 108 USD | +1.69% |
|
+6.47% | +8.57% |
| 24/04 | Sector Update: Health Care Stocks Slipping Late Afternoon | MT |
| 24/04 | Moderna to Collaborate With OpenAI to Launch New Generation of Medicines | MT |
| Sales 2024 * | 4.21B 351B | Sales 2025 * | 4.83B 403B | Capitalization | 41.34B 3,447B |
|---|---|---|---|---|---|
| Net income 2024 * | -2.81B -234B | Net income 2025 * | -2.08B -173B | EV / Sales 2024 * | 8.7 x |
| Net cash position 2024 * | 4.73B 395B | Net cash position 2025 * | 3.38B 282B | EV / Sales 2025 * | 7.86 x |
| P/E ratio 2024 * |
-14.9
x | P/E ratio 2025 * |
-20.3
x | Employees | 5,600 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.39% |
More Fundamentals
* Assessed data
More news
Latest transcript on Moderna, Inc.
More recommendations
More press releases
More news
| 1 day | +1.69% | ||
| 1 week | +6.47% | ||
| Current month | +1.32% | ||
| 1 month | +0.52% | ||
| 3 months | +6.05% | ||
| 6 months | +42.10% | ||
| Current year | +8.57% |
1 week
99.30
111.29
1 month
97.00115.89
Current year
84.06115.97
1 year
62.55142.79
3 years
62.55497.49
5 years
11.54497.49
10 years
11.54497.49
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 51 | 01/11/01 |
James Mock
DFI | Director of Finance/CFO | 47 | 06/22/06 |
Stephen Hoge
PSD | President | 48 | 01/13/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul Sagan
BRD | Director/Board Member | 65 | 01/18/01 |
| Director/Board Member | 74 | 01/20/01 | |
Francois Nader
BRD | Director/Board Member | 67 | 11/19/11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.66% | 0 M€ | 0.00% | - | |
| 4.69% | 2 M€ | -.--% | ||
| 4.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 108 | +1.69% | 2,247,093 |
| 25/24/25 | 106.2 | -2.45% | 2,798,459 |
| 24/24/24 | 108.8 | +0.89% | 3,410,216 |
| 23/24/23 | 107.9 | +3.28% | 2,435,253 |
| 22/24/22 | 104.5 | +3.01% | 3,176,356 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
02/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
108
USD
Average target price
134.3
USD
Spread / Average Target
+24.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.57% | 41.34B | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B | |
| -16.98% | 10.07B |
- Stock Market
- Equities
- MRNA Stock
